| [1] |
Maresca R, Mignini I, Varca S, et al. Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together[J]. Int J Mol Sci, 2024, 25(6): 3278.
|
| [2] |
Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease[J]. Nat Rev Microbiol, 2023, 21(11): 719-733.
|
| [3] |
Navarro P, Gutiérrez-Ramírez L, Tejera-Muñoz A, et al. Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease[J]. Nutrients, 2023, 15(21): 4507.
|
| [4] |
Dias E, Andrade P, Lopes S, et al. Liver biopsy in inflammatory bowel disease patients with sustained abnormal liver function tests: a retrospective single-center study[J]. Ann Gastroenterol, 2023, 36(1): 54-60.
|
| [5] |
Trifan A, Stafie R, Rotaru A, et al. Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter[J]. J Clin Med, 2022, 11(19): 5959.
|
| [6] |
Kodali A, Okoye C, Klein D, et al. Crohn's Disease is a Greater Risk Factor for Nonalcoholic Fatty Liver Disease Compared to Ulcerative Colitis: A Systematic Review[J]. Cureus, 2023, 15(8): e42995.
|
| [7] |
Aggarwal M, Garg R, Parthasarthy G, et al. Crohn's Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease[J]. Dig Dis Sci, 2023, 68(3): 1006-1015.
|
| [8] |
Martínez-Domínguez SJ, García-Mateo S, Laredo V, et al. Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review[J]. Cancers(Basel), 2023, 15(13): 3367.
|
| [9] |
Boustany A, Rahhal R, Mitri J, et al. The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review[J]. Eur J Gastroenterol Hepatol, 2023, 35(10): 1067-1074.
|
| [10] |
Hyun HK, Lee HW, Park J, et al. Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease[J]. Gut Liver, 2024, 18(2): 294-304.
|
| [11] |
Ritaccio G, Stoleru G, Abutaleb A, et al. Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare[J]. Dig Dis Sci, 2021, 66(9): 3186-3191.
|
| [12] |
Zhong Z, Xu M, Ge C, et al. Exploring shared molecular signatures and regulatory mechanisms in nonalcoholic steatohepatitis and inflammatory bowel disease using integrative bioinformatics analysis[J]. Sci Rep, 2024, 14(1): 12085.
|
| [13] |
Harbord M, Annese V, Vavricka SR, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease[J]. J Crohns Colitis, 2016, 10(3): 239-54.
|
| [14] |
Beheshti Maal A, Shahrbaf MA, Sadri B, et al. Prevalence of Hepatobiliary Manifestations in Inflammatory Bowel Disease: A GRADE Assessed Systematic Review and Meta-Analysis of more than 1. 7 Million Patients[J]. J Crohns Colitis, 2024, 18(3): 360-374.
|
| [15] |
Khrom M, Long M, Dube S, et al. Comprehensive Association Analyses of Extraintestinal Manifestations in Inflammatory Bowel Disease[J]. Gastroenterology, 2024, 167(2): 315-332.
|
| [16] |
Noorian S, Jeon Y, Nguyen MT, et al. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis[J]. Inflamm Bowel Dis, 2022, 28(6): 878-887.
|
| [17] |
Zhang Q, Liu S, Wu J, et al. Non-alcoholic fatty liver degree and long-term risk of incident inflammatory bowel disease: A large-scale prospective cohort study[J]. Chin Med J(Engl), 2024, 137(14): 1705-1714.
|
| [18] |
Chen J, Dan L, Tu X, et al. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study[J]. Hepatol Int, 2023, 17(1): 202-214.
|
| [19] |
Shu Y, Yang B, Liu X, et al. Causal effects from inflammatory bowel disease on liver function and disease: a two-sample Mendelian randomization study[J]. Front Med(Lausanne), 2024, 10: 1320842.
|
| [20] |
Chen L, Fan Z, Sun X, et al. Mendelian Randomization Rules Out Causation Between Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease[J]. Front Pharmacol, 2022, 13: 891410.
|
| [21] |
Rodriguez-Duque JC, Calleja JL, Iruzubieta P, et al. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors[J]. Clin Gastroenterol Hepatol, 2023, 21(2): 406-414.
|
| [22] |
Nagata T, Funakoshi S, Morihara D, et al. Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study[J]. Intest Res, 2023, 21(4): 471-480.
|
| [23] |
Adolph TE, Meyer M, Jukic A, et al. Heavy arch: from inflammatory bowel diseases to metabolic disorders[J]. Gut, 2024, 73(8): 1376-1387.
|
| [24] |
Michaudel C, Danne C, Agus A, et al. Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases[J]. Gut, 2023, 72(7): 1296-1307.
|
| [25] |
Hedin CRH, Vavricka SR, Stagg AJ, et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy[J]. J Crohns Colitis, 2019, 13(5): 541-554.
|
| [26] |
Magrì S, Paduano D, Chicco F, et al. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history[J]. World J Gastroenterol, 2019, 25(37): 5676-5686.
|
| [27] |
Maitiabula G, Tian F, Wang P, et al. Liver PP2A-Cα Protects From Parenteral Nutrition-associated Hepatic Steatosis[J]. Cell Mol Gastroenterol Hepatol, 2022, 14(3): 669-692.
|
| [28] |
Hunt JE, Billeschou A, Windeløv JA, et al. Pharmacological activation of TGR5 promotes intestinal growth via a GLP-2- dependent pathway in mice[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318(5): G980-G987.
|
| [29] |
Mai H, Yang X, Xie Y, et al. The role of gut microbiota in the occurrence and progression of non-alcoholic fatty liver disease[J]. Front Microbiol, 2024, 14: 1257903.
|
| [30] |
De Caro C, Spagnuolo R, Quirino A, et al. Gut Microbiota Profile Changes in Patients with Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease: A Metagenomic Study[J]. Int J Mol Sci, 2024, 25(10): 5453.
|
| [31] |
Zhu G, Chen L, Liu S, et al. Celecoxib-mediated attenuation of non-alcoholic steatohepatitis is potentially relevant to redistributing the expression of adiponectin receptors in rats[J]. Heliyon, 2022, 8(7): e09872.
|
| [32] |
Potoupni V, Georgiadou M, Chatzigriva E, et al. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis[J]. J Gastroenterol Hepatol, 2021, 36(11): 3002-3014.
|
| [33] |
Hwang N, Kang D, Shin SJ, et al. Creeping fat exhibits distinct Inflammation-specific adipogenic preadipocytes in Crohn's disease[J]. Front Immunol, 2023, 14: 198905.
|
| [34] |
Besharat S, Sakhavi F, Sookhtehsaraei P, et al. Non-alcoholic fatty liver disease(NAFLD) and obesity in inflammatory bowel disease(IBD) patients in Gorgan[J]. Caspian J Intern Med, 2024, 15(2): 299-306.
|
| [35] |
Trivedi HD, Lopes EW, Glissen Brown J, et al. Steroid Use and Risk of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-analysis[J]. J Clin Gastroenterol, 2023, 57(6): 610- 616.
|
| [36] |
Perez-Carreras M, Casis-Herce B, Rivera R, et al. Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach[J]. World J Gastroenterol, 2021, 27(41): 7113-7124.
|